We have located links that may give you full text access.
Long Term Outcomes After Invasive Treatment of Carotid Artery Stenosis: a Longitudinal Study of German Health Insurance Claims.
OBJECTIVE: There is a paucity of observational data including long term outcomes after invasive treatment for carotid artery stenosis.
METHODS: This retrospective study utilised nationwide insurance claims from the third largest provider in Germany, DAK-Gesundheit. Patients who underwent inpatient carotid endarterectomy (CEA) or carotid artery stenting (CAS) between 1 January 2008 and 31 May 2017 were included. The Elixhauser comorbidity scores from longitudinally linked hospital episodes were utilised. Kaplan-Meier analysis and log-rank test were used to determine long term stroke-free survival. Multivariable regression models were developed to adjust for confounding.
RESULTS: A total of 22 637 individual patients (41.6% female, median age 72.5 years) were included, of whom 15 005 (66.3%) were asymptomatic and 17 955 (79.3%) underwent CEA. After a median of 48 months, 5 504 any stroke or death events were registered. The mortality rate varied between 0.4% (CEA of asymptomatic stenosis) and 2.1% (urgent CAS of acute stroke patients) at 30 days, and between 4.1% and 8.4% at 1 year, respectively. The rate for any stroke varied between 0.6% (CEA of asymptomatic stenosis) and 2.5% (CAS of symptomatic patients) at 30 days, and between 2.5% and 6.4% at 1 year, respectively. The combined rate for any stroke and mortality at 1 year was 6.3% (CEA of asymptomatic stenosis), 8.7% (CAS of asymptomatic stenosis), and 12.5% (urgent CAS of acute stroke patients). After 5 years, the overall stroke rate was 7.4% after CEA and 9.0% after CAS. In adjusted analyses, both older age and van Walraven comorbidity score were associated with events, while treatment of asymptomatic stenosis was associated with lower event rates.
CONCLUSION: The current study revealed striking differences between previous landmark trials and real world practice. It further suggested excess mortality of invasively treated asymptomatic patients.
METHODS: This retrospective study utilised nationwide insurance claims from the third largest provider in Germany, DAK-Gesundheit. Patients who underwent inpatient carotid endarterectomy (CEA) or carotid artery stenting (CAS) between 1 January 2008 and 31 May 2017 were included. The Elixhauser comorbidity scores from longitudinally linked hospital episodes were utilised. Kaplan-Meier analysis and log-rank test were used to determine long term stroke-free survival. Multivariable regression models were developed to adjust for confounding.
RESULTS: A total of 22 637 individual patients (41.6% female, median age 72.5 years) were included, of whom 15 005 (66.3%) were asymptomatic and 17 955 (79.3%) underwent CEA. After a median of 48 months, 5 504 any stroke or death events were registered. The mortality rate varied between 0.4% (CEA of asymptomatic stenosis) and 2.1% (urgent CAS of acute stroke patients) at 30 days, and between 4.1% and 8.4% at 1 year, respectively. The rate for any stroke varied between 0.6% (CEA of asymptomatic stenosis) and 2.5% (CAS of symptomatic patients) at 30 days, and between 2.5% and 6.4% at 1 year, respectively. The combined rate for any stroke and mortality at 1 year was 6.3% (CEA of asymptomatic stenosis), 8.7% (CAS of asymptomatic stenosis), and 12.5% (urgent CAS of acute stroke patients). After 5 years, the overall stroke rate was 7.4% after CEA and 9.0% after CAS. In adjusted analyses, both older age and van Walraven comorbidity score were associated with events, while treatment of asymptomatic stenosis was associated with lower event rates.
CONCLUSION: The current study revealed striking differences between previous landmark trials and real world practice. It further suggested excess mortality of invasively treated asymptomatic patients.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app